Investigational Treatment for Hypereosinophilic Syndrome Granted Orphan Drug Status Posted on April 30, 2019 at 9:12 am. Written by saturnadmin Orphan Drug designation allows companies a 7-year marketing exclusivity period, should the treatment be approved. Click to View Article × Comments are closed.
Comments are closed.